The ranked assignee list is heavily top-weighted: a single leading assignee holds 1,614 of the 3,535 records in scope, and the top five together account for 78.9% of all records. Fifth place holds 169 records and tenth place 65, showing a steep drop after the leaders rather than a gradual taper. Several of the largest holders are linked through shared named inventors on early foundational patents, which later consolidated into corporate portfolios, so counting by company alone can understate how concentrated the underlying research lineage actually is.

Filing volume peaked in 2019 at 207 records and has since settled into a plateau: complete-year data shows 82 filings in 2021 against 83 in 2024, a span of just +1%. That is neither strong growth nor a decline, but a mature, steady-state filing rate. Figures for 2025 and 2026 appear lower in the raw count, but that reflects the roughly 18-month lag between filing and publication rather than an actual drop in activity, so those years should not be read as a downturn.

C12N, covering microorganisms and genetic engineering, appears on 70.5% of the 3,535 records in scope, and A61K, medicinal preparations, on 63.0%. C07K, peptides and proteins, is close behind at 62.8%. These three classes together indicate the field is anchored in cell and molecular engineering claims rather than device engineering alone, even though mechanoporation devices are a growing recent theme. Measurement and testing-oriented classes such as C12Q, G01N and C07H each cover under a third of records, marking comparatively lighter claim density there.